| Ticker | EDIT |
|---|---|
| ISIN | US28106W1036 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also i...
El precio actual de Editas Medicine, Inc. (EDIT) es de 2,91 , con una variación del -9,35%.
Editas Medicine, Inc. opera en el sector Healthcare, industria Biotechnology.